GoodRx Holdings, Inc. (GDRX) Income Statement
GDRX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsGDRX revenue and net income
Where GDRX's revenue goes
2025Each bar shows an amount and its share of revenue. GDRX kept 3.8% of revenue as net income.
GDRX profit margins
GDRX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +0.6% | +1.3% | +7.7% | — |
| Gross profit | −0.7% | +1.8% | +7.2% | — |
| Operating income | +32.9% | +269.2% | — | — |
| Net income | +85.7% | — | — | — |
| EPS (diluted) | +6.1% | +5.3% | −61.8% | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GDRX quarterly EPS vs estimates
GoodRx beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 3, 2026 (estimate $0.04).
GDRX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $796.9M | $792.3M | $750.3M | $766.6M | $745.4M | $550.7M | $388.2M | $249.5M | $157.2M | $99.4M |
| Cost of revenue | $57.6M | $48.2M | $66.9M | $65.1M | $46.7M | $29.6M | $14.0M | $6.0M | $12.2M | $10.3M |
| Gross profit | $739.3M | $744.1M | $683.3M | $701.5M | $698.7M | $521.1M | $374.2M | $243.5M | $145.1M | $89.1M |
| Research & development | $121.0M | $123.7M | $135.8M | $143.1M | $125.9M | $61.8M | $29.3M | $43.9M | $11.5M | $5.7M |
| Sales, general & admin | $445.5M | $485.0M | $466.8M | $502.4M | $524.9M | $716.6M | $191.7M | $112.5M | — | — |
| Total operating expenses | $651.8M | $678.3M | $710.3M | $699.7M | $685.3M | $796.8M | $234.5M | $166.2M | $94.8M | $70.1M |
| Operating income | $87.5M | $65.8M | −$27.0M | $1.7M | $13.4M | −$275.7M | $139.7M | $77.3M | $50.3M | $18.9M |
| Interest income | $10.9M | $23.3M | $29.1M | $9.3M | $59,000 | $160,000 | $715,000 | $154,000 | — | — |
| Interest expense | $42.6M | $52.9M | $56.7M | $34.2M | $23.6M | $27.9M | $49.6M | $22.2M | $7.0M | $3.5M |
| Income before taxes | $56.5M | $31.5M | −$55.6M | −$23.2M | −$10.2M | −$303.4M | $83.0M | $52.3M | $39.7M | $15.1M |
| Income taxes | $26.1M | $15.1M | −$46.7M | $9.6M | $15.1M | −$9.8M | $16.9M | $8.6M | $10.9M | $6.2M |
| Net income | $30.4M | $16.4M | −$8.9M | −$32.8M | −$25.3M | −$293.6M | $66.0M | $43.8M | $8.8M | −$7.8M |
| EBITDA | $184.4M | $153.9M | $108.8M | $65.2M | $48.0M | −$257.1M | $146.1M | $84.3M | $59.4M | $28.0M |
| EPS (diluted) | $0.35 | $0.33 | $0.28 | $0.30 | $0.33 | $42.88 | $0.18 | $0.37 | — | — |
| Gross margin | 92.8% | 93.9% | 91.1% | 91.5% | 93.7% | 94.6% | 96.4% | 97.6% | 92.3% | 89.6% |
| Operating margin | 11.0% | 8.3% | −3.6% | 0.2% | 1.8% | −50.1% | 36.0% | 31.0% | 32.0% | 19.0% |
| Net margin | 3.8% | 2.1% | −1.2% | −4.3% | −3.4% | −53.3% | 17.0% | 17.6% | 5.6% | −7.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $200.4M | $194.0M | $194.8M | $196.0M | $203.1M | $203.0M | $198.6M | $195.3M | $200.6M | $197.9M | $196.6M | $180.0M |
| Cost of revenue | $21.0M | $41.9M | $17.5M | $13.4M | $33.1M | $13.4M | $12.2M | $11.7M | $11.9M | $12.5M | $15.2M | $18.7M |
| Gross profit | $179.4M | $152.1M | $177.3M | $182.6M | $170.0M | $189.6M | $186.4M | $183.6M | $188.7M | $185.4M | $181.5M | $161.2M |
| Research & development | $26.7M | $30.2M | $28.9M | $31.0M | $29.9M | $31.1M | $31.7M | $30.1M | $30.9M | $31.0M | $32.0M | $39.6M |
| Sales, general & admin | $106.8M | $26.8M | $102.6M | $115.5M | $113.2M | $114.2M | $117.4M | $115.5M | $121.0M | $131.1M | $124.1M | $126.9M |
| Total operating expenses | $155.8M | $132.5M | $154.6M | $168.0M | $142.3M | $166.2M | $168.2M | $163.2M | $168.9M | $178.0M | $199.8M | $199.6M |
| Operating income | $23.6M | $19.5M | $22.7M | $14.6M | $27.7M | $23.4M | $18.2M | $20.4M | $19.9M | $7.4M | −$18.3M | −$38.3M |
| Interest income | $1.0M | $1.4M | $1.9M | $2.3M | $2.8M | $3.9M | $4.6M | $4.8M | $6.3M | $7.6M | $8.5M | $8.6M |
| Interest expense | $9.8M | $9.8M | $10.4M | $10.8M | $10.7M | $10.6M | $11.4M | $12.4M | $14.6M | $14.6M | $14.8M | $14.7M |
| Income before taxes | $15.5M | $5.6M | $14.2M | $6.1M | $19.6M | $16.7M | $11.4M | $8.1M | $11.6M | $293,000 | −$24.6M | −$46.6M |
| Income taxes | $6.9M | $4.5M | $8.8M | $5.0M | $6.7M | $5.6M | $4.7M | $4.1M | $5.0M | $1.3M | $1.2M | −$8.1M |
| Net income | $8.5M | $1.2M | $5.4M | $1.1M | $12.8M | $11.1M | $6.7M | $12.3M | $6.7M | −$1.0M | −$25.9M | −$38.5M |
| EBITDA | $47.5M | $37.2M | $47.7M | $38.4M | $50.0M | $48.2M | $41.9M | $38.0M | $43.2M | $30.9M | $33.8M | $1.1M |
| EPS (diluted) | $0.04 | $0.07 | $0.09 | $0.08 | $0.09 | $0.09 | $0.09 | $0.08 | $0.08 | $0.08 | $0.08 | $0.06 |
| Gross margin | 89.5% | 78.4% | 91.0% | 93.2% | 83.7% | 93.4% | 93.9% | 94.0% | 94.1% | 93.7% | 92.3% | 89.6% |
| Operating margin | 11.8% | 10.1% | 11.6% | 7.5% | 13.6% | 11.5% | 9.2% | 10.5% | 9.9% | 3.7% | −9.3% | −21.3% |
| Net margin | 4.3% | 0.6% | 2.8% | 0.6% | 6.3% | 5.4% | 3.4% | 6.3% | 3.3% | −0.5% | −13.2% | −21.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in GDRX's financial statements (latest annual report filed February 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GDRX financial results
In fiscal year 2025 (ended December 31, 2025), GoodRx reported revenue of $796.9 million, up 0.6% from the year before. It had net income of $30.4 million (up 85.7%), a net profit margin of 3.8%. Diluted earnings per share came to $0.35. Over five years revenue grew at an average rate of 7.7% a year.
See the GDRX stock overview for the latest quote and news, or the GDRX chart for price history and technical indicators.
GDRX income statement FAQ
What is GoodRx's annual revenue?
GoodRx reported total revenue of $796.9 million for fiscal year 2025, which ended on December 31, 2025. That was up 0.6% from $792.3 million the previous year.
Is GoodRx profitable?
Yes. GoodRx reported net income of $30.4 million in fiscal 2025, a net profit margin of 3.8%; its operating margin was 11.0%.
What is GoodRx's gross margin?
GoodRx's gross margin was 92.8% in fiscal 2025: for every $100 of revenue, GoodRx kept $93 after the direct cost of its products and services.
How much does GoodRx spend on research and development?
GoodRx spent $121.0 million on research and development in fiscal 2025, 15.2% of revenue.
How fast is GoodRx growing?
Revenue grew 7.7% a year on average over the last five fiscal years, from $550.7 million to $796.9 million.
What are GoodRx's earnings per share?
GoodRx earned $0.35 per diluted share in fiscal 2025, compared with $0.33 a year earlier.
When will GoodRx report its next earnings?
GoodRx is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes.
When does GoodRx's fiscal year end?
GoodRx's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 25, 2026.